Evidence map›Paper›PMID 33173863›Full record

ArticlebioRxiv : the preprint server for biology2020

A Workflow of Integrated Resources to Catalyze Network Pharmacology Driven COVID-19 Research.

Gergely Zahoránszky-Kőhalmi, Vishal B Siramshetty, Praveen Kumar, Manideep Gurumurthy, Busola Grillo, Biju Mathew, Dimitrios Metaxatos, Mark Backus, Tim Mierzwa, Reid Simon and 9 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Gergely Zahoránszky-KőhalmiNational Center for Advancing Translational Sciences, Rockville, MD, USA.
Vishal B SiramshettyNational Center for Advancing Translational Sciences, Rockville, MD, USA.
Praveen KumarDepartment of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Manideep GurumurthyNational Center for Advancing Translational Sciences, Rockville, MD, USA.
Busola GrilloNational Center for Advancing Translational Sciences, Rockville, MD, USA.
Biju MathewNational Center for Advancing Translational Sciences, Rockville, MD, USA.
Dimitrios MetaxatosNational Center for Advancing Translational Sciences, Rockville, MD, USA.
Mark BackusNational Center for Advancing Translational Sciences, Rockville, MD, USA.
Tim MierzwaNational Center for Advancing Translational Sciences, Rockville, MD, USA.
Reid SimonNational Center for Advancing Translational Sciences, Rockville, MD, USA.
Ivan GrishaginNational Center for Advancing Translational Sciences, Rockville, MD, USA.
Laura BrovoldRancho BioSciences LLC., San Diego, CA USA.
Ewy A MathéNational Center for Advancing Translational Sciences, Rockville, MD, USA.
Matthew D HallNational Center for Advancing Translational Sciences, Rockville, MD, USA.
Samuel G MichaelNational Center for Advancing Translational Sciences, Rockville, MD, USA.
Alexander G GodfreyNational Center for Advancing Translational Sciences, Rockville, MD, USA.
Jordi MestresResearch Group on Systems Pharmacology, Research Program on Biomedical Informatics (GRIB), IMIM Hospital del Mar Medical Research Institute and University Pompeu Fabra, Barcelona, Catalonia, Spain.
Lars J JensenNovo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Tudor I OpreaDepartment of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA.

Funding

Illuminating the Druggable Genome Knowledge Management Center (IDG KMC)U54CA189205 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI OPREA, TUDOR I · 2014 to 2017
$5.7M
NCI NIH HHS U54 CA189205
6 · The paper itself

Abstract

motivationIn the event of an outbreak due to an emerging pathogen, time is of the essence to contain or to mitigate the spread of the disease. Drug repositioning is one of the strategies that has the potential to deliver therapeutics relatively quickly. The SARS-CoV-2 pandemic has shown that integrating critical data resources to drive drug-repositioning studies, involving host-host, hostpathogen and drug-target interactions, remains a time-consuming effort that translates to a delay in the development and delivery of a life-saving therapy.

resultsHere, we describe a workflow we designed for a semi-automated integration of rapidly emerging datasets that can be generally adopted in a broad network pharmacology research setting. The workflow was used to construct a COVID-19 focused multimodal network that integrates 487 host-pathogen, 74,805 host-host protein and 1,265 drug-target interactions. The resultant Neo4j graph database named "Neo4COVID19" is accessible via a web interface and via API calls based on the Bolt protocol. We believe that our Neo4COVID19 database will be a valuable asset to the research community and will catalyze the discovery of therapeutics to fight COVID-19. AVAILABILITY: https://neo4covid19.ncats.io.

Identifiers

PMID33173863
PMCPMC7654851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.